Calidi Biotherapeutics (CLDI) Non-Current Deffered Revenue (2021 - 2022)
Calidi Biotherapeutics' quarterly Non-Current Deffered Revenue came in at $8.0 million in Q3 2022, little changed quarter-over-quarter from $8.0 million in Q2 2022.
Calidi Biotherapeutics has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $8.0 million in Q3 2022.
- For the quarter ending Q3 2022, Non-Current Deffered Revenue changed N/A year-over-year to $8.0 million; the trailing twelve-month figure through Sep 2022 stood at $8.0 million (changed N/A YoY), and the FY2021 full-year result was $8.0 million, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q3 2022 stood at $8.0 million, roughly flat from $8.0 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $8.0 million in Q4 2021, with the low at $8.0 million in Q4 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | - |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 225.10 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | - |
| 10 | Calidi Biotherapeutics | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 8.05 Mn |
| Jun 30, 2022 | 8.05 Mn |
| Mar 31, 2022 | 8.05 Mn |
| Dec 31, 2021 | 8.05 Mn |